Can Growth Factors Cure Parkinson's Disease?

被引：28

作者：

Sidorova, Yulia A. ^{[1
]}

Saarma, Mart ^{[1
]}

机构：

[1] Univ Helsinki, Inst Biotechnol, HiLIFE, Helsinki, Finland

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2020年 / 41卷 / 12期

基金：

芬兰科学院;

关键词：

SYNUCLEIN MESSENGER-RNA; BLOOD-BRAIN-BARRIER; NEURONS-IN-VITRO; NEUROTROPHIC FACTOR; DOWN-REGULATION; TYROSINE-HYDROXYLASE; FUSION PROTEIN; CDNF PROTECTS; MOUSE MODEL; LEWY BODY;

D O I：

10.1016/j.tips.2020.09.010

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Growth factors (GFs) hold considerable promise for disease modification in neurodegenerative disorders because they can protect and restore degenerating neurons and also enhance their functional activity. However, extensive efforts applied to utilize their therapeutic potential in humans have achieved limited success so far. Multiple clinical trials with GFs were performed in Parkinson's disease (PD) patients, in whom diagnostic symptoms of the disease are caused by advanced degeneration of nigrostriatal dopamine neurons (DNs), but the results of these trials are controversial. This review discusses recent developments in the field of therapeutic use of GFs, problems and obstacles related to this use, suggests the ways to overcome these issues, and alternative approaches that can be used to utilize the potential of GFs in PD management.

引用

页码：909 / 922

页数：14

共 91 条

[1] α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration [J].

Abdelmotilib, Hisham ;

Maltbie, Tyler ;

Delic, Vedad ;

Liu, Zhiyong ;

Hu, Xianzhen ;

Fraser, Kyle B. ;

Moehle, Mark S. ;

Stoyka, Lindsay ;

Anabtawi, Nadia ;

Krendelchtchikova, Valentina ;

Volpicelli-Daley, Laura A. ;

West, Andrew .

NEUROBIOLOGY OF DISEASE, 2017, 105 :84-98

[2]

Airavaara Mikko, 2020, Curr Protoc Neurosci, V91, pe88, DOI 10.1002/cpns.88

[3] CDNF Protects the Nigrostriatal Dopamine System and Promotes Recovery After MPTP Treatment in Mice [J].

Airavaara, Mikko ;

Harvey, Brandon K. ;

Voutilainen, Merja H. ;

Shen, Hui ;

Chou, Jenny ;

Lindholm, Paivi ;

Lindahl, Maria ;

Tuominen, Raimo K. ;

Saarma, Mart ;

Hoffer, Barry ;

Wang, Yun .

CELL TRANSPLANTATION, 2012, 21 (06) :1213-1223

[4] AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models [J].

Albert, Katrina ;

Voutilainen, Merja H. ;

Domanskyi, Andrii ;

Airavaara, Mikko .

GENES, 2017, 8 (02)

[5] Intranasal Delivery of pGDNF DNA Nanoparticles Provides Neuroprotection in the Rat 6-Hydroxydopamine Model of Parkinson's Disease [J].

Aly, Amirah E. -E. ;

Harmon, Brendan T. ;

Padegimas, Linas ;

Sesenoglu-Laird, Ozge ;

Cooper, Mark J. ;

Waszczak, Barbara L. .

MOLECULAR NEUROBIOLOGY, 2019, 56 (01) :688-701

[6] Exenatide and the treatment of patients with Parkinson's disease [J].

Aviles-Olmos, Iciar ;

Dickson, John ;

Kefalopoulou, Zinovia ;

Djamshidian, Atbin ;

Ell, Peter ;

Soderlund, Therese ;

Whitton, Peter ;

Wyse, Richard ;

Isaacs, Tom ;

Lees, Andrew ;

Limousin, Patricia ;

Foltynie, Thomas .

JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (06) :2730-2736

[7] Safety and efficacy of neublastin in painful lumbosacral radiculopathy: a randomized, double-blinded, placebo-controlled phase 2 trial using Bayesian adaptive design (the SPRINT trial) [J].

Backonja, Miroslav ;

Williams, Leslie ;

Miao, Xiaopeng ;

Katz, Nathaniel ;

Chen, Crystal .

PAIN, 2017, 158 (09) :1802-1812

[8] Conserved roles of C. elegans and human MANFs in sulfatide binding and cytoprotection [J].

Bai, Meirong ;

Vozdek, Roman ;

Hnizda, Ales ;

Jiang, Chenxiao ;

Wang, Bingying ;

Kuchar, Ladislav ;

Li, Tiejun ;

Zhang, Yuefan ;

Wood, Chase ;

Feng, Liang ;

Dang, Yongjun ;

Ma, Dengke K. .

NATURE COMMUNICATIONS, 2018, 9

[9] Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies [J].

Bartus, R. T. ;

Kordower, J. H. ;

Johnson, E. M., Jr. ;

Brown, L. ;

Kruegel, B. R. ;

Chu, Y. ;

Baumann, T. L. ;

Lang, A. E. ;

Olanow, C. W. ;

Herzog, C. D. .

NEUROBIOLOGY OF DISEASE, 2015, 78 :162-171

[10] Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: Where do we stand and where must we go next? [J].

Bartus, Raymond T. ;

Johnson, Eugene M., Jr. .

NEUROBIOLOGY OF DISEASE, 2017, 97 :169-178

← 1 2 3 4 5 6 7 8 9 10 →